Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY-NC-NDEuropean urology open science

Oligoprogressive Renal Cell Carcinoma Treated with Stereotactic Body Radiation Therapy Versus Switching to a New Systemic Therapy

  • Ciro Franzese1
  • Matteo Perrino2
  • Nadia Cordua1
  • Fabio De Vincenzo2
  • Raffaella Lucchini3
  • Marta Aliprandi1
  • Lorenzo Lo Faro3
  • Luigi Cecchi1
  • Luciana Di Cristina3
  • Alessandro Bertocchi2
  • Anna Bertolini1
  • Antonio Federico1
4 more authors
  • Federica Borea2
  • Laura Giordano4
  • Marta Scorsetti1
  • Paolo Andrea Zucali1
4 affiliations
  1. 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
  2. 2Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy
  3. 3Humanitas Clinical and Research Center - IRCCS, Humanitas Research Hospital, Rozzano (MI), Italy
  4. 4Biostatistic Unit, IRCCS Humanitas Research Hospital, Milan, Italy
Read full textPDFCite

Related

  1. Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinoma.
    Nicholas J Salgia, Adil Khan, Yu Fujiwara +8
    Journal for immunotherapy of cancerPeer-reviewedCC BY-NCFull textImmunologyOncologyEurope PMC
  2. Multidisciplinary approach with stereotactic reirradiation to oligoprogressive spinal metastases from dedifferentiated osteosarcoma: a case report
    Arkadiusz Moskwa, Paulina Chmiel, Katarzyna Kozak +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefDOAJ
  3. Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
    Jin Li, Nianlan Zhou, Saiquan Lu +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref
  4. Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma : A Phase 2 Nonrandomized Clinical Trial
    Raquibul Hannan, Lin Lin, Ryan Assadi +13
    JAMA oncologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. A prospective pilot study of urine microRNA as a biomarker of urinary radiation toxicity following MRI-guided prostate stereotactic body radiotherapy.
    Urszula Smyczyńska, Zuzanna Nowicka, Patrick Doyle +7
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{franzese2026oligoprogressive,
  title = {{Oligoprogressive Renal Cell Carcinoma Treated with Stereotactic Body Radiation Therapy Versus Switching to a New Systemic Therapy}},
  author = {Ciro Franzese and Matteo Perrino and Nadia Cordua and Fabio De Vincenzo and Raffaella Lucchini and Marta Aliprandi and Lorenzo Lo Faro and Luigi Cecchi and Luciana Di Cristina and Alessandro Bertocchi and Anna Bertolini and Antonio Federico and Federica Borea and Laura Giordano and Marta Scorsetti and Paolo Andrea Zucali},
  journal = {European urology open science},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13673049},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Oligoprogressive Renal Cell Carcinoma Treated with Stereotactic Body Radiation Therapy Versus Switching to a New Systemic Therapy
AU  - Ciro Franzese
AU  - Matteo Perrino
AU  - Nadia Cordua
AU  - Fabio De Vincenzo
AU  - Raffaella Lucchini
AU  - Marta Aliprandi
AU  - Lorenzo Lo Faro
AU  - Luigi Cecchi
AU  - Luciana Di Cristina
AU  - Alessandro Bertocchi
AU  - Anna Bertolini
AU  - Antonio Federico
AU  - Federica Borea
AU  - Laura Giordano
AU  - Marta Scorsetti
AU  - Paolo Andrea Zucali
PY  - 2026
DA  - 2026/10/05
JO  - European urology open science
UR  - https://europepmc.org/article/PMC/PMC13673049
SN  - 2666-1691
SN  - 2666-1683
ER  -